Pathfinder Cell Therapy (EM)【PFND】銘柄情報

Pathfinder Cell Therapy Inc (EM) (PFND) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.000001

( - )

買値

0.00

売値

0.00

出来高

0.00 日の範囲 0.00

0.000001 52 週間の範囲 0.000001

時価総額

667.161

前日終値

0.000001

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 1,000

発行済株式数

667,160,870

配当利回り

PER

-0

1 株当たり利益 (EPS)

-0

歳入

純利益

-1.08M

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial... Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.pathfindercelltherapy.com

本社

Cambridge, United States

設立

2026

Pathfinder Cell Therapy Inc (EM) is listed in the Healthcare sector of the その他OTC with ticker PFND. The last closing price for Pathfinder Cell Therapy (EM) was US$0. Over the last year, Pathfinder Cell Therapy (EM) shares have traded in a share price range of US$ 0.000001 to US$ 0.000001.

Pathfinder Cell Therapy (EM) currently has 667,160,870 shares in issue. The market capitalisation of Pathfinder Cell Therapy (EM) is US$667.16 . Pathfinder Cell Therapy (EM) has a price to earnings ratio (PE ratio) of -0.00.

Pathfinder Cells Stimulate Improved Kidney Function and Facilitate Repair of Kidney Tissue Damage Following Acute Kidney Injury

Pathfinder Cells Stimulate Improved Kidney Function and Facilitate Repair of Kidney Tissue Damage Following Acute Kidney Injury Preclinical Data...

Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND), a biotechnology...

Pathfinder to Present at New York Stem Cell Summit

CAMBRIDGE, Mass., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND), a biotechnology...

Pathfinder Announces First European Patent Allowance for Pathfinder Cells

CAMBRIDGE, Mass., Feb. 15, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND), a biotechnology...

Pathfinder Cell Therapy Provides Update on Pathfinder Cell Research and Development

CAMBRIDGE, Mass., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder") (OTCQB:PFND), a biotechnology company focused on...

Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol

Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol PR Newswire CAMBRIDGE, Mass., Sept. 16, 2011 CAMBRIDGE, Mass., Sept. 16, 2011...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	1.0E-6	1.0E-6	1.0E-6	0	0	CS
26	0	0	1.0E-6	1.0E-6	1.0E-6	143	1.0E-6	CS
52	0	0	1.0E-6	1.0E-6	1.0E-6	550	1.0E-6	CS
156	0	0	1.0E-6	1.0E-6	1.0E-6	706	1.0E-6	CS
260	-0.010999	-99.9909090909	0.011	0.02	1.0E-6	34216	0.0037813	CS